Mesenchymal Stem Cell Carriers for Newcastle Oncolytic Viruses: The New Era in Colorectal Cancer treatment

Colorectal cancer (CRC) is positioned as the third most widespread form of cancer on a global scale, affecting both males and females. Furthermore, it holds the unfortunate title of being the second leading cause of deaths associated with cancer, and it remains the primary contributor to mortality in cases of gastrointestinal cancer. CRC specifically affects the colon and rectum, resulting from the abnormal growth of glandular epithelial cells in the colon. CRC treatment options encompass a range of interventions such as surgical procedures, radiation therapy, chemotherapy, and additional modalities. However, these treatments often come with side effects that can make the patient's journey exhausting. Therefore, there is a pressing need for new treatment approaches that can minimize these side effects. In recent years, oncolytic viruses have gained substantial attention from researchers as a promising approach in the field of cancer treatment. However, there have been obstacles to overcome, such as the immune system's interference, preventing the oncolytic virus from functioning effectively and neutralizing it before it reaches the tumor. To address this challenge, a carrier is required to ensure safe delivery of the virus to the tumor site. Mesenchymal cells have emerged as potential candidates for facilitating virus transmission due to their favorable properties as carriers. In this article, we delve into the application of mesenchymal cells as carriers for Newcastle Oncolytic Virus in the treatment of colorectal cancer. Our objective through this research is to make significant contributions to the advancement of novel and enhanced methodologies in combating this particular disease.